Daniel P. Petrylak, MD, presented “Enfortumab Vedotin Approved by FDA for Patients With Refractory Urothelial Carcinoma” for the Grand Rounds in Urology audience in January, 2020.
How to cite: Petrylak, Daniel P. “Enfortumab Vedotin Approved by FDA for Patients With Refractory Urothelial Carcinoma” January, 2020. Accessed May 2021. https://grandroundsinurology.com/enfortumab-vedotin-approved-by-fda-for-patients-with-refractory-urothelial-carcinoma/
Enfortumab Vedotin Approved by FDA for Patients With Refractory Urothelial Carcinoma – Summary:
Daniel P. Petrylak, MD, Director of Genitourinary Oncology, Professor of Medicine and of Urology, and Co-Director of the Signal Transduction Program at Yale University Cancer Center, discusses the recent FDA approval of the antibody drug complex enfortumab vedotin for treating refractory advanced urothelial disease in patients previously treated with immunotherapy and chemotherapy. He describes how the drug complex works to fight bladder cancer by recognizing Nectin-4, a biomarker expressed on the surface of bladder cancer cells, and delivering MMAE to cause cytotoxic activity. Dr. Petrylak further describes the design, execution, and results of the clinical trial that led to the drug’s approval, as well as notable side effects.